New drug targets Alzheimer's proteins in Early-Onset patients
NCT ID NCT05231785
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a drug called ALN-APP (mivelsiran) in 60 adults with mild cognitive impairment or mild dementia due to early-onset Alzheimer's disease. The drug is given via a spinal injection to see if it safely lowers certain proteins linked to Alzheimer's in the brain. The study will first test a single dose, then multiple doses over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALN-APP (mivelsiran)
What this could lead to
If successful, this could point toward a treatment that slows or modifies early-onset Alzheimer's disease progression.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, focused on safety and dosing. It may not show any benefit, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-ONSET ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
COMPLETEDLa Jolla, California, 92037, United States
-
Clinical Trial Site
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Clinical Trial Site
RECRUITINGMontreal, H3A 2B4, Canada
-
Clinical Trial Site
RECRUITINGToronto, M3B 2S7, Canada
-
Clinical Trial Site
RECRUITINGAmsterdam, 1081 BT, Netherlands
-
Clinical Trial Site
COMPLETEDGroningen, 9713 GG, Netherlands
-
Clinical Trial Site
RECRUITINGHuntley Street, WC1E 6AG, United Kingdom
-
Clinical Trial Site
RECRUITINGSheffield, S10 2JF, United Kingdom